Navigation Links
Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
Date:2/22/2008

Primary Endpoint of the Trial to Be Clarified with FDA

WALTHAM, Mass., Feb. 22 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC Bulletin Board: ABOS) announced today that the Company has received conditional approval from the U.S. Food and Drug Administration ("FDA") of an Investigational Device Exemption ("IDE") to begin the pivotal clinical trial for SEPET(TM), Arbios' extracorporeal (outside the body) artificial liver assist device for blood purification of chronically ill patients suffering from acute liver failure. Permission was granted to initiate the trial while the Company responds to the FDA's conditions and request for additional information. In particular, FDA has requested a survival primary endpoint, which could potentially increase the total number of patients required for the trial. The trial design proposed by the Company has a primary endpoint of a two-stage drop in hepatic encephalopathy and its secondary endpoints include several survival based endpoints. The Company is refining its position that a two-stage drop in hepatic encephalopathy is clinically meaningful and an appropriate primary endpoint for the trial. The Company is requesting a meeting with FDA to discuss this issue and to confirm the overall design of the trial.

"While we are pleased to have received FDA permission to start the SEPET pivotal trial, we will work diligently with FDA with the hope of identifying a mutually acceptable primary endpoint," commented CEO and President Shawn Cain. "We currently do not have the financial resources to fund the pivotal trial and our ability to finance the Company is contingent upon, among other issues, agreement on a primary endpoint with a reasonable number of patients required for the trial."

"Hepatic encephalopathy ("HE") represents one of the most frequent complications of cirrhosis mandating hospitalization and a two-stage improvement of HE has significant clinical benefits to patients," noted Dr. John
'/>"/>

SOURCE Arbios Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Reported at American Association for Cancer Research ... -- Favrille,Inc. , a biopharmaceutical company developing ... announced,results from a new study showing enhanced ... key component in the Company's,Id/KLH immunotherapy product ...
... Origin May Be Useful in Cancer Treatment,Decisions , ... Inc.,(NASDAQ: MYGN) (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today ... might be used to,determine the original location of ... the annual meeting of the American Association,for Cancer ...
Cached Medicine Technology:Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 2Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 3Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 4Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... teenagers have a lot in common: Sugary soda. Fast-food ... Low-income teenagers are almost three times more likely to ... to new research from the UCLA Center for Health ... 21 percent of teenagers living in low-income families are ...
... Calif., Dec. 10 ThermoGenesis,Corp. (Nasdaq: KOOL ... process and store adult stem cells, said today that ... (POC) products under the,Vantus brand. Unveiling of the ... 54th Annual Convention of the American Association of Equine,Practitioners ...
... HONOLULU, Dec. 10 Hoana Medical announced today that ... at the Institute for Healthcare Improvement (IHI) premier event ... leaders in hospital,safety. , ... conjunction with the,IHI event, to introduce its LifeGurney system, ...
... prostate cancer patients with drugs that block hormonal activity ... from cardiovascular disease, according to a study led by ... report from members of the same study team found ... risk of diabetes and heart disease, the current study ...
... A group of nutritionists from Extenso, the Universit de ... chefs from the Institut de tourisme et d,htellerie du ... and early childhood centres. The goal is to help ... for kids. , The nutrition team will provide its ...
... Ga., Dec. 10 Joe Jurevicius, Tom Brady, ... few months the list,of top professional football players ... read as a who,s who of the National ... infections is healthcare facilities,where athletes are undergoing surgeries, ...
Cached Medicine News:Health News:Obesity among state's low-income teens nearly triple that of more affluent peers 2Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 2Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 3Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 4Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 2Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 3Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 4Health News:Hormone therapy for prostate cancer does not appear to increase cardiac deaths 2Health News:Hormone therapy for prostate cancer does not appear to increase cardiac deaths 3Health News:New partnership to foster healthier food habits in early childhood 2Health News:Staph Infections Hit Professional Football Hard 2Health News:Staph Infections Hit Professional Football Hard 3
Pocket-sized instrument with direct illumination. Avaliable in black, green or blue....
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
... delivers power and reliability with proprietary ... Diode side-pumping technology drives 2.5 W ... Spectra system, and active resonator temperature ... system reliability from your first treatment ...
Medicine Products: